Market Closed -
Nasdaq
04:00:00 2024-07-15 pm EDT
5-day change
1st Jan Change
444.5
USD
+0.33%
+9.57%
+45.00%
Medpace Holdings, Inc.(NasdaqGS:MEDP) added to S&P Composite 1500
January 02, 2019 at 12:00 am EST
Medpace Holdings, Inc. will be added to the S&P Composite 1500
Make way for earnings season
Jul. 12
Analyst recommendations: Albemarle, Snowflake, Tesla, Diageo, Johnson Matthey...
Jul. 12
Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating
Jul. 08
MT
Medpace Holdings, Inc. Announces Board and Committee Changes
Jul. 03
CI
Medpace Holdings Insider Sold Shares Worth $3,081,617, According to a Recent SEC Filing
Jun. 07
MT
Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing
May. 29
MT
TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target
May. 29
MT
Mizuho Starts Medpace Holdings With Buy Rating, $435 Price Target
May. 28
MT
Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing
May. 22
MT
Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing
May. 17
MT
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing
May. 14
MT
Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing
May. 08
MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing
May. 03
MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing
May. 01
MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating
Apr. 24
MT
Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Apr. 23
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450
Apr. 23
MT
Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance
Apr. 22
MT
Medpace Guides For FY 2024 GAAP EPS of $10.79-$11.47 on Revenue of $2.15-$2.2 Billion, vs CIQ Analyst Consensus of $10.57/Share on Revenue of $2.18 Billion
Apr. 22
MT
Earnings Flash (MEDP) MEDPACE HOLDINGS Posts Q1 Revenue $511M, vs. Street Est of $512M
Apr. 22
MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022.
Apr. 22
CI
Medpace Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 22
CI
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024
Apr. 22
CI
North American Morning Briefing : Stock Futures -2-
Apr. 22
DJ
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target
Mar. 18
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Average target price
430.5
USD
Spread / Average Target
-2.83%
Consensus
1st Jan change
Capi.
+45.00% 13.69B +22.15% 46.55B +45.94% 41.84B -2.37% 40.84B +33.84% 32.95B -6.35% 28.27B +20.42% 27.78B +48.83% 14.26B +0.06% 12.18B -8.52% 11.14B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
MEDPACE HOLDINGS, INC. 
